These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19004724)

  • 1. [New predictive factors for chemosensitivity of breast cancers].
    Bonnefoi H; de Cremoux P
    Bull Cancer; 2008 Oct; 95(10):943-50. PubMed ID: 19004724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.
    Rody A; Karn T; Gätje R; Ahr A; Solbach C; Kourtis K; Munnes M; Loibl S; Kissler S; Ruckhäberle E; Holtrich U; von Minckwitz G; Kaufmann M
    Breast; 2007 Feb; 16(1):86-93. PubMed ID: 17010609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
    Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
    Slamon DJ; Press MF
    J Natl Cancer Inst; 2009 May; 101(9):615-8. PubMed ID: 19401550
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?
    Bonnefoi H; Underhill C; Iggo R; Cameron D
    Eur J Cancer; 2009 Jul; 45(10):1733-43. PubMed ID: 19477634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.
    Sekine I; Shimizu C; Nishio K; Saijo N; Tamura T
    Int J Clin Oncol; 2009 Apr; 14(2):112-9. PubMed ID: 19390941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?
    Pritchard KI
    J Clin Oncol; 2009 Aug; 27(24):3875-6. PubMed ID: 19620479
    [No Abstract]   [Full Text] [Related]  

  • 9. Doubling back on centromere 17 in early breast cancer.
    Bedard PL; Desmedt C
    Lancet Oncol; 2010 Mar; 11(3):216-7. PubMed ID: 20202603
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HER2 and topoisomerase II alpha: useful clinical markers in breast cancer].
    Larsimont D; Durbecq V; Awada A; Di Leo A
    Bull Cancer; 2008 Mar; 95(3):344-51. PubMed ID: 18390415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
    Simon R
    J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
    [No Abstract]   [Full Text] [Related]  

  • 16. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
    Buzdar AU
    J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721
    [No Abstract]   [Full Text] [Related]  

  • 17. The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.
    Mano MS; Rosa DD; De Azambuja E; Ismael GF; Durbecq V
    Cancer Treat Rev; 2007 Feb; 33(1):64-77. PubMed ID: 17113234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of biologic parameters for primary chemotherapy in operable breast cancer.
    Frassoldati A; Maur M; Guarneri V; Nicolini M; Conte PF
    Clin Breast Cancer; 2005 Oct; 6(4):315-24. PubMed ID: 16277881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer-associated gene abnormalities and chemosensitivity].
    Sakamoto M; Umayahara K; Sakamoto H; Kawasaki K; Suehiro Y; Kunugi T; Akiya T; Iwabuchi H; Sakunaga H; Muroya T; Kikuchi Y; Sugishita T; Tenjin Y; Gray JW; Tanaka T
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1819-31. PubMed ID: 9797804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
    Hannemann J; Kristel P; van Tinteren H; Bontenbal M; van Hoesel QG; Smit WM; Nooij MA; Voest EE; van der Wall E; Hupperets P; de Vries EG; Rodenhuis S; van de Vijver MJ
    Br J Cancer; 2006 Nov; 95(10):1334-41. PubMed ID: 17088909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.